Volume 27, Issue 136, June 2023

Cytoreductive nephrectomy plus targeted therapy in patients with metastatic renal cell carcinoma: Our experience

Vishal Kadeli¹, Mahesh Kalloli², Shridhar C Ghagane³, Nerli RB^1♦, Rangrez Shadab¹, Murigendra B Hiremath⁴

¹Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Nehru Nagar, Belagavi-590010, India
²Department of Surgical Oncology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Nehru Nagar, Belagavi-590010, India
³Department of Biotechnology, KAHER’s Dr Prabhakar Kore Basic Science Research Center, 3rd Floor, VK Institute of Dental Sciences Campus, Nehru Nagar, Belagavi-590010, India
⁴Department of Biotechnology and Microbiology, Karnataka University, Dharwad-580003, India

^♦Corresponding author
Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Nehru Nagar, Belagavi-590010, India

ABSTRACT

Introduction: Renal cell carcinoma presents with metastatic disease in approximately 30% of cases. Since the introduction of targeted therapies, they have demonstrated impressive gains in overall survival, progression-free survival and response rates over the previously utilized immunotherapies in cases with mRCC. The rates of cytoreductive nephrectomy have declined since the introduction of targeted therapy. We report our experience with cytoreductive nephrectomy plus targeted therapy. Materials & Methods: We retrospectively collected the hospital inpatient and outpatient records of mRCC who had undergone cytoreductive nephrectomy trailed by targeted treatment. Data included demographic, clinical, imaging and laboratory data and those that were found to have prognostic value. Measured outcomes included OS. Results: 78 patients (61 males and 17 females) 60.17± 8.76 years was mean age who underwent cytoreductive nephrectomy for mRCC of clear cell type. 43 (55.1%) patients had comorbidity. 78 patients had huge renal masses (mean 10.167±2.756 cms) on CT imaging. All patients were introduced on target therapy four to eight weeks after surgery. The mean overall survival of the patients was 27.98±1.47 months. Conclusions: Presently the important role of cytoreductive nephrectomy is not well defined in the ear of targeted therapy. However, in our study patient with good performance statuses do better than patients with existing health risks.

Keywords: Metastatic, Renal cancer, Cytoreductive nephrectomy, Targeted therapy

Medical Science, 2023, 27, e246ms2668

PDF

DOI: https://doi.org/10.54905/disssi/v27i136/e246ms2668

Published: 05 June 2023